Amgen closes deal for $2.8B stake in oncology firm BeiGene
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
New drugs boost profits at Amgen as two executives leave company
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen earnings per share up 20 percent due to higher product sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
European Union approves Amgen’s Xgeva to treat multiple myeloma
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen wins new FDA approval for cancer drug Xgeva
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen asks FDA to consider new uses for Xgeva
Thousand Oaks-based biotech giant Amgen announced June 19 that the U.S. Food and Drug Administration has accepted a supplemental application for Xgeva (denosumab) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. “Multiple Read More →
Amgen reports revenue increase in second quarter earnings
Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →
